Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies

This article provides billing and coding instructions for Next-Generation Sequencing lab-developed tests for myeloid malignancies and suspected myeloid malignancies, including required claim fields and identifiers. Key requirements: report the appropriate CPT and ICD-10-CM codes, include the DEX Z-Code adjacent to the CPT code in specified Part A and Part B claim fields, and submit exactly 1 unit of service; do not add extra characters to the DEX Z-Code on SV101-7.

"Bill this policy's procedures when submitting claims for Next-Generation Sequencing (NGS) lab-developed tests (LDTs) for myeloid malignancies or suspected myeloid malignancies."

Sign up to see full coverage criteria, indications, and limitations.